DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
September 05 2018 - 8:00AM
DiaMedica Therapeutics Inc. (the “
Company” and
“
DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) announces
the recent appointment of Harry Alcorn Jr. Pharm.D. as Chief
Medical Officer where he will oversee global clinical development
and regulatory initiatives for DiaMedica. Dr Alcorn has
over 30 years of clinical research experience working with public
and private biotech and pharmaceutical companies in studies of
kidney diseases and diabetic, hepatic and cardiovascular patients.
He has designed, authored and been a consultant to a multitude of
companies in the industry on protocol development, clinical
execution and regulatory guidance. He has served as Principal
Investigator or Sub Investigator in over 450 clinical studies and
has assisted many biotech and pharmaceutical companies in
negotiating protocols and presenting results to the FDA. Dr.
Alcorn has presented at numerous international meetings and
industry seminars discussing the critical challenges in conducting
patient studies.
Prior to joining DiaMedica, Dr. Alcorn served as
Chief Scientific Officer at DaVita Clinical Research (DaVita), a
company that provides clinical research services for pharmaceutical
and biotech companies. During this time, he also served on
the Board of Directors for The Association of Clinical Pharmacology
Units and on the Board of Directors of MedTox
Laboratories. In 2000 Dr. Alcorn started the US Renal
Network, the first organization to coordinate clinical trial sites
for the conduct of kidney studies. Prior to DaVita he held
the position of Executive Director and led the clinical trials at
GalaGen Inc, a biopharmaceutical company developing
therapeutics to target life-threatening and emerging pathogens.
Dr. Alcorn obtained his Bachelor of Pharmacy from
Creighton University and his Doctor of Pharmacy from University of
Nebraska Medical Center. He currently holds clinical
faculty appointments with the University of Minnesota, Creighton
University, University of Nebraska Medical Center, Virginia
Commonwealth and the University of Colorado, Denver.
“We are thrilled that Harry is bringing to
DiaMedica his strong industry and operational leadership at a time
when we are preparing to initiate clinical research in patients
with Chronic Kidney disease” commented Rick Pauls, President and
CEO of DiaMedica. “His knowledge, experience in patient trials,
along with his work as a subject matter expert for both industry
and the FDA, complements our team.”I am very excited to join
DiaMedica at this stage of its development,” said Dr. Alcorn.
“DiaMedica is leading the investigation of the KLK1 protein and has
the opportunity to significantly improve the lives of patients
suffering from chronic kidney disease and neurological disorders. I
look forward to helping the company accelerate the development of
DM199 for these patients.”
About DM199DM199 is a
recombinant (synthetic) form of the human protein known as “KLK1”.
The KLK1 protein plays an important role in the regulation of
diverse physiological processes including blood flow, inflammation,
fibrosis, oxidative stress and neurogenesis via a molecular
mechanism that increases production of nitric oxide and
prostacyclin. KLK1 deficiency may play a role in multiple vascular
and fibrotic diseases such as chronic kidney disease, retinopathy,
stroke, vascular dementia and treatment resistant hypertension
where current treatment options are limited or ineffective.
DiaMedica is the first company to have developed a recombinant form
of the KLK1 protein. The KLK1 protein, produced from porcine
pancreas and human urine, has been used to treat patients in Japan,
China and Korea for decades. DM199 is currently being studied in
patients with acute ischemic stroke and DiaMedica is preparing to
initiate a clinical study in patients with chronic kidney
disease.
About DiaMedica Therapeutics
Inc.
DiaMedica Therapeutics is a clinical stage
biopharmaceutical company focused on developing novel treatments
for neurological and kidney diseases. DiaMedica’s shares are listed
on the TSX Venture Exchange under the trading symbol “DMA” and on
the OTCQB under the trading symbol “DMCAF”. For more information,
please visit www.diamedica.com. Follow us on
social media – Twitter,
LinkedIn.
For further information, please
contact:
Paul Papi Vice President of Business Development
DiaMedica Therapeutics Inc. Two Carlson Parkway, Suite 260
Minneapolis, MN Phone: (617) 899-5941 info@diamedica.com
Tweet this!
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024